No Data
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $14
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Express News | Fulcrum Therapeutics Inc : Leerink Partners Raises Target Price to $16 From $14
Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data
INFN, VYGR and AMSC Are Among After Hour Movers